Reuters logo
2 months ago
BRIEF-Sierra Oncology Receives clearance to enhance ongoing clinical trials for SRA737
May 10, 2017 / 11:15 AM / 2 months ago

BRIEF-Sierra Oncology Receives clearance to enhance ongoing clinical trials for SRA737

1 Min Read

May 10 (Reuters) - Sierra Oncology Inc:

* Says received clearance from regulators in UK to amend two ongoing phase 1 trials for its CHK1 inhibitor, SRA737

* Sierra Oncology Receives clearance to enhance ongoing clinical trials for SRA737

* Says amended trials will include cohort expansions of prospectively selected patients with tumors

* Says an initial update from these trials is anticipated in early 2018

* Says study will now consist of two phases, a dose escalation phase and a cohort expansion phase, being run concurrently Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below